Evidence map›Paper›PMID 32738178›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2020

Bivalent engagement of endothelial surface antigens is critical to prolonged surface targeting and protein delivery in vivo.

R Yu Kiseleva, P G Glassman, K M LeForte, L R Walsh, C H Villa, V V Shuvaev, J W Myerson, P A Aprelev, O A Marcos-Contreras, V R Muzykantov and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

R Yu KiselevaDepartment of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
P G GlassmanDepartment of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
K M LeForteDepartment of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
L R WalshDepartment of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
C H VillaDepartment of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
V V ShuvaevDepartment of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
J W MyersonDepartment of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
P A AprelevDepartment of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
O A Marcos-ContrerasDepartment of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
V R MuzykantovDepartment of Pharmacology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
C F GreinederDepartment of Emergency Medicine and Pharmacology, University of Michigan, Ann Arbor, MI, USA.
University of Pennsylvania · USUniversity of Michigan–Ann Arbor · US

Funding

TRANSFUSION MEDICINE RESEARCH TRAINING PROGRAMT32HL007775 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI SIEGEL, DONALD LAWRENCE · 1993 to 2023
$2.8M
Targeted nanomedicine for ALI and I/RR01HL125462 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2015 to 2018
$2.3M
Targeting novel biotherapeutics to endotheliumR01HL128398 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2015 to 2018
$2.2M
Endothelial targeting of antioxidantsR01HL126874 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2016 to 2019
$1.7M
ICAM-1 targeted thrombomodulin: an experimental therapeutic for the Acute Respiratory Distress SyndromeK08HL130430 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI GREINEDER, COLIN FRED · 2016 to 2020
$665k
HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) K08-HL130430HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) RO1 HL125462HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) RO1 HL128398NHLBI NIH HHS K08 HL130430NHLBI NIH HHS R01 HL125462NHLBI NIH HHS R01 HL126874NHLBI NIH HHS R01 HL128398NHLBI NIH HHS T32 HL007775
6 · The paper itself

Abstract

Targeted drug delivery to the endothelium has the potential to generate localized therapeutic effects at the blood-tissue interface. For some therapeutic cargoes, it is essential to maintain contact with the bloodstream to exert protective effects. The pharmacokinetics (PK) of endothelial surface-targeted affinity ligands and biotherapeutic cargo remain a largely unexplored area, despite obvious translational implications for this strategy. To bridge this gap, we site-specifically radiolabeled mono- (scFv) and bivalent (mAb) affinity ligands specific for the endothelial cell adhesion molecules, PECAM-1 (CD31) and ICAM-1 (CD54). Radiotracing revealed similar lung biodistribution at 30 minutes post-injection (79.3% ± 4.2% vs 80.4% ± 10.6% ID/g for αICAM and 58.9% ± 3.6% ID/g vs. 47.7% ± 5.8% ID/g for αPECAM mAb vs. scFv), but marked differences in organ residence time, with antibodies demonstrating an order of magnitude greater area under the lung concentration vs. time curve (AUC

Indexed as

AnimalsAntibodies, MonoclonalDrug Delivery SystemsEndothelial CellsEndothelium, VascularHumansIntercellular Adhesion Molecule-1LigandsLungPlatelet Endothelial Cell Adhesion Molecule-1Single-Chain AntibodiesTissue DistributionAntibodies, MonoclonalIntercellular Adhesion Molecule-1LigandsPlatelet Endothelial Cell Adhesion Molecule-1Single-Chain Antibodiescell surfaceendotheliumICAM-1PECAM-1targeted drug deliverythrombomodulin

Identifiers

PMID32738178
PMCPMC8444999
OpenAlexW3046221565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.